The Personalised Cancer Medicine Program at Karolinska Institutet
The Personalised Cancer Medicine (PCM)-program at Karolinska Institutet (KI) is a research-based initiative to implement modern precision cancer medicine.
The purpose of the program is to facilitate PCM-related cancer research, aiming at future personalised cancer management in clinical routine practice. Achieved by catalysing synergies between existing and developing research and health care.
One aim is to develop a comprehensive pipeline for early clinical trials, as one instrumental core facility in a future Comprehensive Cancer Centre (CCC) at KI and the University Hospital. A CCC will be the basis for translational cancer research involving the “Theme Cancer” of the New Karolinska Hospital and the basic cancer research of KI.
The PCM program was initiated in 2014 with funding from Radiumhemmets Forskningsfonder. Professors Ingemar Ernberg and Rolf Lewensohn together with a steering group appointed by the KICancer Research Network chair the program. Claes Karlsson, MD, PhD, serves as the program director since december 2015.